For China, in addition to common targets for hematological tumors, there has been an increase in trials for some less common targets in solid tumors, such as CLDN18.2, HER2, and MSLN in recent years [32]. This evidence concerns the gene MSLN and hematopoietic and lymphoid cell neoplasm.